Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer

BACKGROUND: Both clinical and genomic data independently predict survival and treatment response in early-stage HER2-positive breast cancer. Here we present the development and validation of a new HER2DX risk score, and a new HER2DX pathological complete response (pCR) score, both based on a 27-gene...

Descripción completa

Detalles Bibliográficos
Autores principales: Prat, Aleix, Guarneri, Valentina, Pascual, Tomás, Brasó-Maristany, Fara, Sanfeliu, Esther, Paré, Laia, Schettini, Francesco, Martínez, Débora, Jares, Pedro, Griguolo, Gaia, Dieci, Maria Vittoria, Cortés, Javier, Llombart-Cussac, Antonio, Conte, Benedetta, Marín-Aguilera, Mercedes, Chic, Nuria, Puig-Butillé, Joan Anton, Martínez, Antonio, Galván, Patricia, Tsai, Yi-Hsuan, González-Farré, Blanca, Mira, Aurea, Vivancos, Ana, Villagrasa, Patricia, Parker, Joel S., Conte, Pierfranco, Perou, Charles M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741424/
https://www.ncbi.nlm.nih.gov/pubmed/34990895
http://dx.doi.org/10.1016/j.ebiom.2021.103801

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741424/
https://www.ncbi.nlm.nih.gov/pubmed/34990895
http://dx.doi.org/10.1016/j.ebiom.2021.103801

Ejemplares similares